Disease diversity and FLT3 mutations

被引：5
|
作者：
Smith, Catherine Choy [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2013年 / 110卷 / 52期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; GASTROINTESTINAL STROMAL TUMORS; KINASE DOMAIN MUTATIONS; THERAPEUTIC TARGET; ITD MUTATIONS; RESISTANCE; VALIDATION; ACTIVATION; GEFITINIB;
D O I：
10.1073/pnas.1320579110
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：20860 / 20861
页数：2
相关论文
共 50 条
  • [21] High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage
    Borowczyk, Martyna
    Szczepanek-Parulska, Ewelina
    Debicki, Szymon
    Budny, Bartlomiej
    Janicka-Jedynska, Malgorzata
    Gil, Lidia
    Verburg, Frederik A.
    Filipowicz, Dorota
    Wrotkowska, Elzbieta
    Majchrzycka, Blanka
    Marszalek, Andrzej
    Ziemnicka, Katarzyna
    Ruchala, Marek
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [22] FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
    Kiyoi, Hitoshi
    Kawashima, Naomi
    Ishikawa, Yuichi
    CANCER SCIENCE, 2020, 111 (02) : 312 - 322
  • [23] Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors
    Marensi, Vanessa
    Keeshan, Karen R.
    MacEwan, David J.
    BIOCHEMICAL PHARMACOLOGY, 2021, 183
  • [24] FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    BLOOD RESEARCH, 2022, 57 : 32 - 36
  • [25] The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
    Minson, Katherine A.
    Smith, Catherine C.
    DeRyckere, Deborah
    Libbrecht, Clara
    Lee-Sherick, Alisa B.
    Huey, Madeline G.
    Lasater, Elisabeth A.
    Kirkpatrick, Gregory D.
    Stashko, Michael A.
    Zhang, Weihe
    Jordan, Craig T.
    Kireev, Dmitri
    Wang, Xiaodong
    Frye, Stephen V.
    Earp, H. Shelton
    Shah, Neil P.
    Graham, Douglas K.
    JCI INSIGHT, 2016, 1 (03)
  • [26] Use of FLT3 Inhibitors in AML
    Smith, Catherine C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S92 - S94
  • [27] Fathoming Flt3
    Briesewitz, Roger
    BLOOD, 2009, 113 (17) : 3889 - 3890
  • [28] Role of Biomarkers in FLT3 AML
    Wei, Jiao
    Hui, Ai-Min
    Nitika
    CANCERS, 2022, 14 (05)
  • [29] Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
    Alvarado, Yesid
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Estrov, Zeev
    Andreeff, Michael
    Cortes, Jorge E.
    CANCER, 2014, 120 (14) : 2142 - 2149
  • [30] FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    Sato, Takashi
    Yang, Xiaochuan
    Knapper, Steven
    White, Paul
    Smith, B. Douglas
    Galkin, Steven
    Small, Donald
    Burnett, Alan
    Levis, Mark
    BLOOD, 2011, 117 (12) : 3286 - 3293
12345